Welcome to our dedicated page for Pliant Therapeutics news (Ticker: PLRX), a resource for investors and traders seeking the latest updates and insights on Pliant Therapeutics stock.
Pliant Therapeutics, Inc. (Nasdaq: PLRX) is a pioneering clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing breakthrough treatments for fibrotic diseases. The company leverages the therapeutic potential of integrin biology and TGF-β modulation to create therapies that could prevent or even reverse fibrosis, thereby addressing significant unmet medical needs.
Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule dual selective inhibitor of αvß6 and αvß1 integrins. It is currently in development for treating idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA for both IPF and PSC, as well as Orphan Drug Designation from the European Medicines Agency.
The company is actively advancing several clinical programs:
- INTEGRIS-PSC Phase 2a Trial: Recent interim results demonstrated bexotegrast’s potential in treating PSC, showing reductions in Enhanced Liver Fibrosis (ELF) score and PRO-C3 levels with statistical significance at the 160 mg dose.
- BEACON-IPF Phase 2b/3 Trial: This adaptive trial design aims to accelerate the development timeline by immediately transitioning from Phase 2b to Phase 3 upon enrollment completion.
- PLN-1474: A small molecule selective inhibitor for treating nonalcoholic steatohepatitis (NASH) with liver fibrosis.
- PLN-101095: In Phase 1, this dual-selective inhibitor targets integrins αvß8 and αvß1 for treating solid tumors.
- PLN-101325: A monoclonal antibody agonist targeting muscular dystrophies.
Founded by world-renowned researchers from UCSF, Pliant Therapeutics combines expertise in fibrosis biology and small molecule chemistry to develop novel therapies. The company also aims to build a patient registry to enhance the understanding of fibrotic disease progression and to support biomarker discovery.
With a strong pipeline, significant regulatory designations, and ongoing successful clinical trials, Pliant Therapeutics is well-positioned to make substantial advancements in treating fibrotic diseases. For more information and the latest updates, visit their website or follow them on social media platforms like X, LinkedIn, Facebook, and YouTube.
Rhea-AI Summary
Pliant Therapeutics, Inc. (PLRX) will participate in investor events including the 23rd Annual Needham Virtual Healthcare Conference and Piper Sandler Spring Biopharma Symposium. The company's President, CEO, and Chief Medical Officer will engage in discussions to showcase their novel therapeutics for fibrotic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
-
Rhea-AI Summary
Pliant Therapeutics, Inc. (PLRX) will present four scientific posters at the 2024 American Thoracic Society International Conference. The posters focus on Bexotegrast, a novel therapeutic for fibrotic diseases. The company was also selected for a featured oral presentation on the safety and tolerability of Bexotegrast. The presentations will cover topics like biomarkers of interstitial lung disease progression and TGF-beta inhibition in the fibrotic lung.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.9%
Tags
-
Rhea-AI Summary
Nimbus Therapeutics appoints Dr. Katharine Knobil to its Board of Directors, bringing over 20 years of pharmaceutical research and development experience. Dr. Knobil's expertise will aid in accelerating Nimbus' development programs in oncology, immunology, and metabolism, aiming to bring novel therapies to patients in need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
Rhea-AI Summary
Pliant Therapeutics, Inc. announces the implementation of BEACON-IPF, a pivotal, adaptive Phase 2b/3 trial for bexotegrast in patients with idiopathic pulmonary fibrosis. The trial's acceptance by the EU and global health authorities will expedite late-stage development, shortening the time to Phase 3 data. Additionally, an upsized debt facility with Oxford Finance extends cash runway through 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
-
News
Rhea-AI Summary
Pliant Therapeutics, Inc. reports positive interim data from Phase 2a INTEGRIS-PSC trial and enrollment updates for BEACON-IPF trial. Financial results show increased research and development expenses but strong cash position.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
-
Rhea-AI Summary
Pliant Therapeutics, Inc. (PLRX) will participate in investor conferences in March, with key executives discussing the company's progress in developing therapeutics for fibrotic diseases. The conferences include TD Cowen 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
Rhea-AI Summary
Pliant Therapeutics, Inc. (PLRX) announced their participation in investor events, including the Oppenheimer 34th Annual Healthcare Life Sciences Conference and the Wells Fargo 2024 West Coast Biotech Tour. The company's President and CEO, Bernard Coulie, M.D., Ph.D., and Chief Medical Officer, Éric Lefebvre, M.D., will be participating in a fireside chat on February 13, 2024, at 12:00 p.m. Eastern Time. Members of Pliant's senior management will also meet with investors on February 28, 2024, as part of an invitation-only event hosted by Wells Fargo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
-
Rhea-AI Summary
Pliant Therapeutics, Inc. (Nasdaq: PLRX) announced 12-week interim data from the 320 mg dose group of INTEGRIS-PSC, a Phase 2a clinical trial of bexotegrast in patients with primary sclerosing cholangitis (PSC). The data showed that bexotegrast was well tolerated, reduced liver fibrosis markers, and improved hepatocyte function and bile flow. The 320 mg group met its primary and secondary endpoints, demonstrating antifibrotic effects. The company plans to discuss the data with regulatory authorities to discuss potential next steps.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Pliant Therapeutics, Inc. (PLRX) to present at the 42nd Annual J.P. Morgan Healthcare Conference. Bernard Coulie, M.D., Ph.D., President and CEO, to speak on January 9, 2024, at 7:30 a.m. Pacific Time. Webcast available on Pliant's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
Rhea-AI Summary
Pliant Therapeutics, Inc. (PLRX) announced the presentation of preclinical and clinical data from the INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) at The Liver Meeting® 2023. The late-breaker presentation highlighted positive interim data from the trial, showing the potential of bexotegrast in treating PSC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
FAQ
What is the current stock price of Pliant Therapeutics (PLRX)?
The current stock price of Pliant Therapeutics (PLRX) is $12.73 as of November 20, 2024.
What is the market cap of Pliant Therapeutics (PLRX)?
The market cap of Pliant Therapeutics (PLRX) is approximately 761.9M.
What does Pliant Therapeutics, Inc. specialize in?
Pliant Therapeutics focuses on discovering, developing, and commercializing treatments for fibrotic diseases using integrin biology and TGF-β modulation.
What is bexotegrast (PLN-74809)?
Bexotegrast (PLN-74809) is an oral, small molecule dual selective inhibitor of αvß6 and αvß1 integrins, in development for treating idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).
What are the ongoing clinical trials for bexotegrast?
Ongoing trials include the INTEGRIS-PSC Phase 2a trial and the BEACON-IPF adaptive Phase 2b/3 trial, aiming to treat PSC and IPF, respectively.
What regulatory designations has bexotegrast received?
Bexotegrast has received Fast Track and Orphan Drug Designations from the U.S. FDA and Orphan Drug Designation from the European Medicines Agency for IPF and PSC.
Who are the founders of Pliant Therapeutics?
Pliant Therapeutics was founded by world-renowned researchers from the University of California, San Francisco (UCSF), experts in fibrosis biology and small molecule chemistry.
What other products are in Pliant’s pipeline?
Other products include PLN-1474 for NASH with liver fibrosis, PLN-101095 for solid tumors, and PLN-101325 targeting muscular dystrophies.
How is Pliant Therapeutics advancing fibrotic disease research?
Pliant is building a patient registry to better understand disease progression and support biomarker discovery.
Where can I find more information about Pliant Therapeutics?
For more information, visit the Pliant Therapeutics website and follow them on social media platforms like X, LinkedIn, Facebook, and YouTube.
What recent achievements has Pliant Therapeutics announced?
Recent achievements include positive interim results from the INTEGRIS-PSC Phase 2a trial and the initiation of the BEACON-IPF Phase 2b/3 trial.
How does Pliant Therapeutics contribute to patient care?
Pliant Therapeutics aims to develop novel therapies that prevent or reverse fibrosis, significantly improving patient outcomes in fibrotic diseases.
Pliant Therapeutics, Inc.
Nasdaq:PLRX
PLRX Rankings
PLRX Stock Data
761.89M
59.06M
2.86%
111.68%
11.86%
Biotechnology
Pharmaceutical Preparations
United States of America
SOUTH SAN FRANCISCO